Sat Kartar Shopping LtdQ1 FY26Pharmaceuticals & Biotechnology

Sat Kartar Shopping Ltd

Q1 FY26 Earnings Call Analysis

Management growth scorecard

Revenue

Category 2

Margin

Category 1

Fundraise

N/A

Order

Yes

Capex

Yes

3 of 4 growth signals are positive.

Revenue guidance

Category 2

→FY 27 product revenue target: ₹300 crores, driven by:
→ - Current run rate at ₹225 crores with expected 25% growth in current business.
→ - Subsidiaries contributing ~₹22 crores.
→ - US operations adding ₹10-15 crores.
→ - AI efficiencies and nutraceuticals (Ajooni Life Sciences) adding ~₹20 crores.
→FY 28 product revenue target: ₹500 crores, fueled by:
→ - New high-ticket products.
→ - Better product margins.
→ - Controlled advertisement spend.
→ - Increased ticket size and scaling sales.
→Hospital business expansion:
→ - 300 beds target by end FY 27, starting simultaneous set-up of 4 facilities.
→ - Plan to expand to 1000 beds by FY 28.
→ - Hospital margins expected at 30-35% at 60% occupancy.
→ - Blended margin (product + hospital) expected at 18-20% by H1 FY 28.
→Growth to come from wider geographic penetration beyond strongholds (TN, UP).

Category 1

→FY26 PAT margin grew from 6% to 8.5% with revenue growth from 160 to 200 crore.
→FY27 target: Revenue growth from 200 to 300 crore; PAT margin targeted at 11-12%.
→FY28 target: Revenue expected to cross 500 crore with blended margin including hospital business reaching 18-20%.
→Hospital business at 60% occupancy expected to deliver 30-35% margin; higher occupancy exponentially increases margins.
→Operating leverage from fixed costs expected to improve profitability as revenues scale.
→AI optimization is improving ROI by 4-5%, expected to further enhance margins over time.
→Subsidiaries expected to grow from ₹1.2 crores revenue in FY26 to 25-30 crore in FY27, supporting overall profit growth.
→No immediate plans for equity dilution; future funding for expansion may come from debt.
→Overall, significant margin expansion and profit growth planned via scaling products and hospital beds, with EPS expected to benefit accordingly.

Get access to all 5 sections — revenue, margin, fundraise, orderbook, and capex — for Sat Kartar Shopping Ltd and 1,400+ other companies.

→The company plans to fund any shortfall in working capital primarily through debt.
→Currently, there is no plan for further equity dilution or raising funds through equity.
→The company has raised around ₹45 crores in capital, which will support the first phase of hospital expansion.
→Cash generation from hospitals and the company’s core business is expected to fund the second phase of hospital growth.
→Overall, debt is the preferred mode of additional fundraising if required, with no immediate plans for equity fundraising.

Yes

→As per the transcript on page 7, the number of orders can be estimated by dividing revenue by ticket size: FY26 revenue was ₹200 crores and ticket size around ₹3,250, implying approximately 6.15 million orders.
→Current business run rate is around ₹225 crores, expecting growth to ₹300 crores in FY27 with new initiatives contributing additional ₹50-₹55 crores.
→Growth drivers include subsidiaries, US operations, AI improvements, nutraceuticals via Ajooni Life Sciences, and geographic expansion in under-penetrated markets.
→Company is focusing on deepening reach from strong pockets like Tamil Nadu, North Uttar Pradesh, Madhya Pradesh, and Maharashtra, aiming to increase order volume through wider pan-India presence.
→Repeat patient orders are stable around 25-26%, supporting recurring order inflow.

Yes

→Current capex includes upgrading existing manufacturing facility (capsule and powder units) with an investment of around ₹1-1.25 crore.
→Hospital bed setup capex is estimated at ₹7-8 lakhs per bed, with ₹4 lakhs considered as fixed asset cost and the balance as working capital.
→For the planned 1000 beds, estimated capex is around ₹40 crore (₹4 lakh per bed).
→Capital for initial phases of hospital expansion raised with ₹45 crore in the bank to build the first phase.
→Subsequent phases to be funded through internal cash generation and possibly debt; no current plans for further equity dilution.
→No plan to produce all products in-house; focus on scaling with collaborations and selective manufacturing upgrades.
→US subsidiary investment awaiting RBI approval, expected operational soon, no capital cited beyond standard overseas direct investment processes.

How does Sat Kartar Shopping Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Sat Kartar Shopping Ltd

Rev 2Mar 1

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Sat Kartar Shopping Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.